$FTRE

Fortrea acquired Worldwide Clinical Trials' early-phase services division for $45M to speed up studies. United Therapeutics gained FDA approval for a lung disease treatment. Pfizer announced layoffs at NC facilities. Several companies made leadership changes and investments. UNC Pembroke offers free biomanufacturing training.

Fortrea (FTRE) and Omico have partnered to accelerate precision oncology research in Australia. The collaboration combines Fortrea's clinical trial expertise with Omico's Precision Oncology Screening Platform (PrOSPeCT) to improve trial planning, site selection, and patient recruitment for biomarker-driven studies. Omico's network includes over 23,000 consented patients and 1,600 clinicians. The initiative aims to expand access to targeted therapies and clinical trials for cancer patients.

UBS raised its price target for Fortrea Holdings Inc. from $22 to $24 while maintaining a neutral rating. The company recently announced management changes, including the reinstatement of Jason Knoblauch as CFO. Fortrea's stock has seen a 32.38% increase year-to-date.

Fortrea (Nasdaq: FTRE) acquired the Early Phase Services division from Worldwide Clinical Trials, adding a 200-bed clinical research unit, a 60,000-square-foot bioanalytical lab, and a biospecimen storage facility. This expands Fortrea's early-phase capacity to 570 beds globally and enhances its clinical development platform. The acquisition is valued at approximately $120 million and is expected to create long-term value for shareholders, according to the company.

US futures decline as global AI sector selloff intensifies, with Korea's Kospi entering a bear market and CoreWeave bonds in distress. Anthropic's Q3 revenue growth slows, and Gartner warns of potential AI infrastructure impairment. Treasuries rally, with 10Y yields dropping 10bps to 5.08%. S&P 500, Nasdaq 100, and SOX indices fell yesterday. Premarket, Apple gains while other Mag-7 and AI-related stocks slide. Gold rises as AngloGold Ashanti is upgraded by Goldman Sachs.

Fortrea Holdings Inc. (FTRE) stock rose 3.8% in pre-market trading after Deutsche Bank upgraded it to Buy with a $25 price target, citing confidence in its recovery. Zacks Research downgraded it to Strong Sell. The company's Q3 2026 earnings release is scheduled for October 29. The broader market is down due to inflation concerns, but FTRE's advance is notable.

Fortrea Holdings Inc.'s average stock price target increased from $21.5 to $21.73, with a range of $15.5 to $26, according to 11 analysts. This implies a 7% upside from the Oct. 8 closing price. The consensus rating is 'Buy' among 14 analysts, with 6 Buys, 6 Holds, and 2 Sells.

Pacific Biosciences (PACB), Fortrea (FTRE), Alamar (ALMR), 10x Genomics (TXG), and Azenta (AZTA) reached 52-week highs on October 6, 2026. PACB announced a collaboration with TychoBio, FTRE reported Q2 revenue of $678M, ALMR saw Q2 revenue surge to $29.43M, TXG launched the Atera platform, and AZTA reported 12% Q3 revenue growth.

Fortrea Holdings (FTRE) stock rose 3.3% premarket after Barclays upgraded it to Overweight with a $38 price target, citing resilient bookings and margin recovery potential. The company reported Q3 revenue of $701.3M, beating estimates, and raised full-year revenue guidance to $2.73B midpoint. FTRE shares are up 34.1% YTD, reaching a 52-week high.

Fortrea Holdings Inc. stock rose 8.7% after Barclays upgraded it to Overweight and raised its price target to $23. The stock hit a 52-week high of $23.51 before closing at $22.95. Barclays cited optimism about the life sciences sector and Fortrea's near-term outlook. UBS also upgraded Fortrea to Hold, and the company has scheduled its Q3 2026 earnings release for October 29. The broader market was positive, with the S&P 500, Dow Jones, and Nasdaq each gaining 0.6%.